HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

alanylalanine (Ala-Ala)

RN given refers to (DL)-isomer
Also Known As:
Ala-Ala; D-Ala-D-Ala; H-Ala-Ala-OH; alanylalanine, (D)-isomer; alanylalanine, (D-Ala)-(L-Ala)-isomer; alanylalanine, (L)-isomer; alanylalanine, (L-Ala)-(D-Ala)-isomer; alanylalanine, (L-Ala)-(DL-Ala)-isomer
Networked: 112 relevant articles (1 outcomes, 9 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Dai, Qiang-Sheng: 2 articles (01/2014 - 01/2014)
2. Hua, Rui-Xi: 2 articles (01/2014 - 01/2014)
3. Ahn, Sang-Gun: 2 articles (01/2012 - 09/2010)
4. Yoon, Jung-Hoon: 2 articles (01/2012 - 09/2010)
5. Mao, Chen: 2 articles (09/2010 - 07/2010)
6. Zhan, Ping: 2 articles (09/2010 - 07/2010)
7. Qiu, Li-Xin: 2 articles (09/2010 - 07/2010)
8. Xue, Kai: 2 articles (09/2010 - 07/2010)
9. Hunter, David J: 2 articles (03/2010 - 12/2008)
10. Hu, Zhibin: 2 articles (11/2009 - 08/2007)

Related Diseases

1. Neoplasms (Cancer)
2. Breast Neoplasms (Breast Cancer)
3. Prostatic Neoplasms (Prostate Cancer)
4. Urinary Bladder Neoplasms (Bladder Cancer)
02/15/2012 - "This study was undertaken to evaluate the clinical value of photodynamic diagnosis (PDD) with intravesical and oral instillation of 5-aminolevulinic acid (ALA) (ALA-PDD), and transurethral resection of bladder tumor (TURBT) guided by ALA-PDD (PDD-TURBT) for nonmuscle invasive bladder cancer. "
10/01/2013 - "Overall, the MTHFR Ala222Val polymorphism was not associated with the development of bladder cancer in all genetic models (Ala/Ala vs. Val/Val--OR = 0.961, 95 % CI = 0.763-1.209; Ala/Ala vs. Ala/Val--OR = 0.918, 95 % CI = 0.795-1.060--Ala/Val vs. Val/Val--OR = 1.022, 95 % CI = 0.852-1.227; dominant model--OR = 0.998, 95 % CI = 0.869-1.145; recessive model--OR = 0.921, 95 % CI = 0.794-1.069; Ala allele vs. Val allele--OR = 0.957, 95 % CI = 0.857-1.067). "
09/01/2012 - "Additionally, patients carrying both Ala/Ala of MnSOD and Leu/Leu of GPX1 had the highest risk of developing bladder cancer. "
10/15/2013 - "Likewise, Ala499Val was also significantly associated with an increased overall cancer risk (Val/Val vs. Ala/Ala: OR = 1.21, 95% CI = 1.07 - 1.36, p = 0.003 and recessive model: OR = 1.20, 95% CI = 1.08 - 1.34, p = 0.001) and further stratification showed an increased risk for breast and bladder cancer, particularly in Asian populations. "
06/01/2008 - "The results for Ala499Val showed a significant overall increase in cancer risk (OR 1.15; 95% CI: 1.02-1.31), and for bladder cancer in both the simple genetic model (Ala/Ala vs Val/Val) (OR 1.30; 95% CI: 1.04-1.61) and the recessive genetic model (Ala/Ala+Ala/Val vs Val/Val) (OR 1.32; 95% CI: 1.06-1.63). "
5. Carcinoma (Carcinomatosis)

Related Drugs and Biologics

1. Estrogen Receptors
2. valylvaline (Val-Val)
3. 1-phenyl-3,3-dimethyltriazene (PDT)
4. Serine Proteases (Serine Protease)
5. Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
6. carbobenzoxy- alanyl- alanyl- borophenylalanyl
7. Doxorubicin (Adriamycin)
8. glutamyl-glutamic acid (Glu-Glu)
9. glutamylalanine
10. prolylvaline

Related Therapies and Procedures

1. Photochemotherapy (Photodynamic Therapy)
2. Semiconductor Lasers
3. Cyclotrons